SCHEMBL20364203

SCHEMBL20364203

Nc1ccc2ncc(C(F)(F)F)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 1/20 0.46
▸ TLR9 Q9NR96 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ EGFR P00533 2/20 0.41
▸ CA2 P00918 1/20 0.40
▸ CHKA P35790 1/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ATM Q13315 2/20 0.40
▸ HTT P42858 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ F2 P00734 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ DRD1 P21728 1/20 0.39
▸ ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702146 1.00 HDAC4 (0.46) HDAC4TLR9KDM4EMAPTEGFR
Hydrochloric Acid SCHEMBL28218349 0.98 HDAC4 (0.45) HDAC4TLR9KDM4EMAPTEGFR
SCHEMBL20364204 0.93 TLR9 (0.50) HDAC4TLR9KDM4EMAPTEGFR
SCHEMBL30702108 0.93 TLR9 (0.50) HDAC4TLR9KDM4EMAPTEGFR
Hydrochloric Acid SCHEMBL28217861 0.91 TLR9 (0.49) HDAC4TLR9KDM4EMAPTEGFR
SCHEMBL1551266 0.82 TLR9 (0.42) TLR9KDM4EMAPTEGFRKMT2A
SCHEMBL20364207 0.79 NQO2 (0.46) HDAC4KDM4EMAPTHTTLMNA
SCHEMBL30134165 0.79 NT5E (0.54) HDAC4KDM4EMAPTHTTLMNA
SCHEMBL31184015 0.79 NQO2 (0.46) HDAC4KDM4EMAPTHTTLMNA
SCHEMBL20364201 0.79 NT5E (0.54) HDAC4KDM4EMAPTHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282748-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-09-11 — — US disclosed
CN-113292539-B Substituted oxopyridine derivatives 拜耳制药股份公司 2023-12-22 — — CN disclosed
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-01-26 — — US disclosed
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-01-26 — — US disclosed
US-11180471-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-11-23 — — US disclosed
US-11180471-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-11-23 — — US disclosed
CN-113292539-A Substituted oxopyridine derivatives 拜耳制药股份公司 2021-08-24 — — CN disclosed
CN-108026072-B Substituted oxopyridine derivatives 拜耳制药股份公司 2021-08-17 — — CN disclosed
EP-3319956-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2021-01-06 — — EP disclosed
EP-3319956-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2021-01-06 — — EP disclosed
US-10421742-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-09-24 — — US disclosed
US-10421742-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-09-24 — — US disclosed
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US disclosed
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US disclosed
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US disclosed
EP-3319956-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2018-05-16 — — EP disclosed
CN-108026072-A Substituted oxopyridine derivatives 拜耳制药股份公司 2018-05-11 — — CN disclosed
WO-2017005725-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421742-B2 Substituted oxopyridine derivatives OGFOD1, VASP, PNPO HDAC4 4036/4885TLR9 2565/4885KDM4E 2356/4885
US-11180471-B2 Substituted oxopyridine derivatives OGFOD1, VASP, PNPO HDAC4 4036/4885TLR9 2565/4885KDM4E 2356/4885
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO HDAC4 4036/4885TLR9 2565/4885KDM4E 2356/4885
US-20250282748-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO HDAC4 4036/4885TLR9 2565/4885KDM4E 2356/4885
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO HDAC4 4036/4885TLR9 2565/4885KDM4E 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback